Atara Biotherapeutics (Atara Biotherapeutics) Days Sales Outstanding : 367.74 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Days Sales Outstanding?

Atara Biotherapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $17.14 Mil. Atara Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $4.25 Mil. Hence, Atara Biotherapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 367.74.

The historical rank and industry rank for Atara Biotherapeutics's Days Sales Outstanding or its related term are showing as below:

ATRA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.06 Med: 118.29 Max: 1582.3
Current: 642

During the past 12 years, Atara Biotherapeutics's highest Days Sales Outstanding was 1582.30. The lowest was 20.06. And the median was 118.29.

ATRA's Days Sales Outstanding is ranked worse than
95.05% of 889 companies
in the Biotechnology industry
Industry Median: 71.97 vs ATRA: 642.00

Atara Biotherapeutics's Days Sales Outstanding declined from Dec. 2022 (8,354.95) to Dec. 2023 (367.74).

Atara Biotherapeutics Days Sales Outstanding Historical Data

The historical data trend for Atara Biotherapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Days Sales Outstanding Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

20.06

118.29

1,582.30

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															8,354.95	1,511.58	43.10	14.30	367.74

Competitive Comparison of Atara Biotherapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Atara Biotherapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Days Sales Outstanding falls into.

Atara Biotherapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Atara Biotherapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (40.221	+	34.108)	/	2 )	/	8.573	*	365
=	37.1645					/	8.573	*	365
=	1,582.30

Atara Biotherapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.163	+	34.108)	/	2 )	/	4.252	*	365 / 4
=	17.1355					/	4.252	*	365 / 4
=	367.74

Atara Biotherapeutics (NAS:ATRA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Atara Biotherapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Executives

Jill Henrich	officer: EVP, Global Head RA & Quality	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon	director, officer: President and CEO	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan	officer: SVP, GC & Secretary	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren	officer: SVP, CFO	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen	officer: EVP, Chief Sci. & Tech Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi	officer: EVP, Chief Medical Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard	officer: EVP, Chief Technical Officer	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont	officer: EVP, Head of R&D	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar	officer: Chief Financial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema	officer: Chief Commercial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell	officer: Chief Tech. Operations Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080